Key result
Growth hormone acutely induces lipolysis and insulin resistance in adipocytes by reducing the expression of FSP27 through MEK/ERK- and STAT5-dependent signaling pathways.
Growth hormone induces lipolysis and insulin resistance in adipocytes by downregulating FSP27 expression via MEK/ERK and STAT5 pathways.
Does not alter GH therapy in humans; leaves open FSP27 as a target in metabolic disease.
Growth hormone (GH) has long been known to stimulate lipolysis and insulin resistance; however, the molecular mechanisms underlying these effects are unknown. In the present study, we demonstrate that GH acutely induces lipolysis in cultured adipocytes. This effect is secondary to the reduced expression of a negative regulator of lipolysis, fat-specific protein 27 (FSP27; aka Cidec) at both the mRNA and protein levels. These effects are mimicked in vivo as transgenic overexpression of GH leads to a reduction of FSP27 expression. Mechanistically, we show GH modulation of FSP27 expression is mediated through activation of both MEK/ERK- and STAT5-dependent intracellular signaling. These two molecular pathways interact to differentially manipulate peroxisome proliferator-activated receptor gamma activity (PPARγ) on the FSP27 promoter. Furthermore, overexpression of FSP27 is sufficient to fully suppress GH-induced lipolysis and insulin resistance in cultured adipocytes. Taken together, these data decipher a molecular mechanism by which GH acutely regulates lipolysis and insulin resistance in adipocytes.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2018) studied Lipolysis and insulin resistance. Growth hormone (GH) was evaluated on Lipolysis and insulin resistance via FSP27 expression. Growth hormone acutely induces lipolysis and insulin resistance in adipocytes by reducing the expression of FSP27 through MEK/ERK- and STAT5-dependent signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: